Biochemical diagnosis of dopaminergic disturbances in paediatric patients: Analysis of cerebrospinal fluid homovanillic acid and other biogenic amines

Clinical Biochemistry

Volumn 41, Issue 16-17, 2008, Pages 1306-1315

  Marín Valencia, Isaac ^a   Serrano, Mercedes ^a   Ormazabal, Aida ^a   Pérez Dueñas, Belén ^a   García Cazorla, Angels ^a   Campistol, Jaume ^a   Artuch, Rafael ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Cerebrospinal fluid; Dopamine deficiency; Homovanillic acid; Neurotransmitters; Paediatric patient

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIQUITIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BRAIN AMINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; DOPAMINE BETA MONOOXYGENASE; HOMOVANILLIC ACID; LEVODOPA; NEUROTRANSMITTER; OXIDOREDUCTASE; PTERIN; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANTIQUITIN DEFICIENCY; AROMATIC AMINO ACID DECARBOXYLASE DEFICIENCY; CATECHOL O METHYLTRANSFERASE DEFICIENCY; CEREBROSPINAL FLUID; DOPAMINE BETA MONOOXYGENASE DEFICIENCY; DOPAMINE DEFICIENCY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; GENETIC DISORDER; HOMOVANILLIC ACID DEFICIENCY; HUMAN; LUMBAR PUNCTURE; MENKES SYNDROME; METABOLIC DISORDER; MONOAMINE OXIDASE A DEFICIENCY; PRIORITY JOURNAL; PTERIN METABOLISM DEFICICENCY; PYRIDOXINE DEFICIENCY; REVIEW; TYROSINE HYDROXYLASE DEFICIENCY;

BIOGENIC AMINES; CHILD; DOPAMINE; HOMOVANILLIC ACID; HUMANS; METABOLIC DISEASES;

EID: 55249109944     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.08.077     Document Type: Review

References (107)

1. Ilias I., and Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm. Metab. Res. 37 (2005) 717-721
2. Strenger V., Kerbl R., Dornbusch H.J., et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr. Blood Cancer 48 (2007) 504-509
3. Nagatsu T., Levitt M., and Uenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 239 (1964) 2910-2917
4. Hyland K., Surtees R.A., Heales S.J., Bowron A., Howells D.W., and Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr. Res. 34 (1993) 10-14
5. Wevers R.A., de Rijk-van Andel J.F., Bräutigam C., et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). J. Inher. Metab. Dis. 22 (1999) 364-373
6. Lüdecke B., Dworniczak B., and Bartolomé K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum. Genet. 95 (1995) 123-125
7. Knappskog P.M., Flatmark T., Mallet J., Lüdecke B., and Bartholomé K. Recessively inherited ldopa-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum. Mol. Genet. 4 (1995) 1209-1212
8. Bräutigam C., Wevers R.A., Jansen R.J., et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin. Chem. 44 (1998) 1897-1904
9. Furukawa Y., Graf W.D., Wong H., Shimadzu M., and Kish S.J. Dopamine responsive dystonia simulating spactic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 56 (2001) 260-263
10. Van der Heuvel L.P., Luiten B., Smeitink J.A., et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive l-dopa-responsive dystonia in the Dutch population. Hum. Genet. 102 (1998) 644-646
11. Lüdecke B., Knappskog P.M., Clayton P.T., et al. Recessively inherited l-dopa responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum. Mol. Genet. 5 (1996) 1023-1028
12. Hyland K. Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J. Nutr. 37 (2007) 1568S-1572S
13. Hoffman G.F., Assmann B., Bräutigam C., et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann. Neurol. 54 (2003) S56-S65
14. Giovanello T., Leuzzi V., Carducci C., et al. Tyrosine hydroxylase deficiency presenting with a biphasic clinical curse. Neuropediatrics 38 (2007) 213-215
15. Møller L.B., Romstad A., Paulsen M., et al. Pre- and postnatal diagnosis of tyrosine hydroxylase deficiency. Prenat. Diagn. 25 (2005) 671-675
16. Nichol C.A., Smith G.K., and Duch D.S. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. Annu. Rev. Biochem. 54 (1985) 729-764
17. Thöny B., Auerbach G., and Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347 (2000) 1-16
18. Blau N., Thöny B., Cotton R., and Hyland K. Disorders of tetrahydrobioterin and related biogenic amines. In: Scriver C., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 1725-1776
19. Bonafe L., Thöny B., Penzien J.M., Czarnecki B., and Blau N. Mutations in the sepiapterin reductase cause a novel tetrahydropterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am. J. Hum. Genet. 69 (2001) 269-277
20. Segawa M., Nomura Y., and Nichiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase 1 deficiency (Segawa disease). Ann. Neurol. 54 (2003) S32-S45
21. Nygaard T.G. Dopa-responsive dystonia. Curr. Opin. Neurol. 8 (1995) 310-313
22. Pearl P.L., Taylor J.L., Trzcinski S., and Sokohl A. The pediatric neurotransmitter disorders. J. Child. Neurol. 22 (2007) 606-616
23. Nemeth A.H. The genetics of primary dystonias and related disorders. Brain 125 (2002) 695-721
24. Neville B.G., Parascandalo R., Farrugia R., and Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 128 (2005) 2291-2296
25. Park Y.S., Heizmann C.W., Wermuth B., et al. Human carbonyl and aldosa reductases: new catalytic functions in tetrahydropterin biosynthesis. Biochem. Biophys. Res. Commun. 175 (1991) 738-744
26. Wermuth B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain: relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J. Biol. Chem. 256 (1981) 1206
27. Abdenur J.E., Abeling N., Specola N., et al. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol. Genet. Metab. 87 (2006) 48-53
28. Pons R., Ford B., Chiriboga C.A., et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology 62 (2004) 1058-1065
29. Swoboda K.J., Saul J.P., McKenna C.E., Speller N.B., and Hyland K. Aromatic l-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann. Neurol. 54 (2003) S49-S55
30. Hyland K., and Clayton P. Aromatic l-aminoacid decarboxylase deficiency: diagnosis methodology. Clin. Chem. 38 (1992) 2405-2410
31. McCormick D.B., and Chen H. Update on interconversions of vitamin B6 with its coenzyme. J. Nutr. 129 (1999) 325-327
32. Mills P.B., Struys E., Jakobs C., Plecko B., Baxter P., and Baumgartner M. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat. Med. 12 (2006) 307-309
33. Ormazábal A., Oppenheim M., Serrano M., et al. Pyridoxal 5'-phosphate values in cerebrospinal fluid: Reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab 94 (2008) 173-177
34. Plecko B., Paul K., Paschke E., et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum. Mutat. 28 (2007) 19-26
35. Mills P.B., Surtees R.A., Champion M.P., et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum. Mol. Genet. 14 (2005) 1077-1086
36. Senard J.M., and Rouet P. Dopamine beta-hydroxylase deficiency. Orphanet. J. Rare. Dis. 1 (2006) 7
37. Robertson D., Goldberg M.R., Hollister A.S., et al. Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired β-hydroxylation of dopamine. New Engl. J. Med. 314 (1986) 1494-1497
38. Hyland K. Disorders of neurotransmitter metabolism. In: Blau N., Duran M., Blaskovics M.E., and Gibson K.M. (Eds). Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases (2002), Springer, Heidelberg 107-122
39. Robertson D., Haile V., and Perry S.E. Dopamine β-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension 18 (1991) 1-8
40. Kim C.H., Zabetian C.P., Cubells J.F., et al. Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am. J. Med. Genet. 108 (2002) 140-147
41. Kaler S.G., Goldstein D.S., Holmes C., Salerno J.A., and Gahl W.A. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann. Neurol. 33 (1993) 171-175
42. Kaler S.G. Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. Am. J. Clin. Nutr. 67 (1998) 1929-1934
43. Shih J.C., Chen K., and Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22 (1999) 197-217
44. Brunner H.G., Nelen M., Breakefield X.O., Ropers H.H., and van Oost B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262 (1993) 578-580
45. Schmidt L.G., Sander T., Kuhn S., et al. Different allele distribution of a regulatory MAOA gene promoter polymorphism in antisocial and anxious-depressive alcoholics. J. Neural. Transm. 107 (2000) 681-689
46. Zalsman G., Huang Y.Y., Harkavy-Friedman J.M., Oquendo M.A., Ellis S.P., and Mann J.J. Relationship of MAO-A promoter (u-VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of caucasians: A preliminary report. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 132 (2005) 100-103
47. Jönsson E.G., Norton N., Gustavsson J.P., Oreland L., Owen M.J., and Sedvall G.C. A promoter polymorphism in the monoamine oxidase: A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J. Psychiatr. Res. 34 (2000) 239-244
48. Ducci F., Newman T.K., Funt S., Brown G.L., Virkkunen M., and Goldman D. A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index. Mol. Psychiatry. 11 (2006) 858-866
49. Ehlis A.C., Reif A., Herrmann M.J., Lesch K.P., and Fallgatter A.J. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 32 (2007) 162-170
50. Lee S.G., Joo Y., Kim B., et al. Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum. Genet. 116 (2005) 319-328
51. Graf W.D., Unis A.S., Yates C.M., et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 57 (2001) 410-416
52. Boot E., Booij J., Zinkstok J., et al. Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology 33 (2008) 1252-1258
53. García-Cazorla A., Serrano M., Pérez-Dueñas B., et al. Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev. Med. Child Neurol. 49 (2007) 740-744
54. Van der Heyden J.C., Rotteveel J.J., and Wevers R.A. Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism. Eur. J. Ped. Neurol. 07 (2003) 31-37
55. Serrano M., Ormazábal A., Pérez-Dueñas B., et al. Perinatal asphyxia may cause reduction in CSF dopamine metabolite concentrations. Neurology 69 (2007) 311-313
56. Gibson K.M., Gupta M., Pearl P.L., et al. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol. Psychiatry. 54 (2003) 763-768
57. Hogema B.M., Gupta M., Senephansiri H., et al. Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat. Genet. 29 (2001) 212-216
58. Pearl P.L., Novotny E.J., Acosta M.T., Jakobs C., and Gibson K.M. Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann. Neurol. 54 (2003) S73-80
59. Burlina A.B., Bonafe L., Ferrari V., Suppiej A., Zacchello F., and Burlina A.P. Measurements of neurotransmitters metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J. Inherit. Metab. Dis. 23 (2000) 313-316
60. Evans A.H., Costa D.C., Gacinovic S., et al. l-Dopa responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. Mov. Dis. 19 (2004) 1232-1236
61. Lykkelund C., Nielsen J.B., Lou H.C., et al. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. Eur. J. Pediatr. 148 (1988) 238-245
62. Lou H.C., Güttler F., Lykkelund C., Bruhn P., and Niederwieser A. Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur. J. Pediatr. 144 (1985) 17-20
63. Lou H.C., Lykkelund C., Gerdes A.M., Udesen H., and Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr. Scand. 76 (1987) 560-565
64. Güttler F., and Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J. Inherit. Metab. Dis. 9 (1986) 169-177
65. García-Cazorla A., Duarte S., Serrano M., et al. Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8 (2008) 273-278
66. Shaywitz B.A., Venes J., Cohen D.J., and Bowers M.B. Reye syndrome: monoamine metabolites in ventricular fluid. Neurology 29 (1979) 467-472
67. Serrano M., Pérez-Dueñas B., Ormazábal A., et al. l-dopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks. Mov. Dis. 23 (2008) 1297-1300
68. Castells S., Chakrabarti C., Winsberg B.G., Hurwic M., Perel J.M., and Nyhan W.L. Effects of l-Nyhan syndrome. J. Autism. Dev. Disord. 9 (1979) 95-103
69. Silverstein F.S., Johnston M.V., Hutchinson R.J., and Edwards N.L. Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities. Neurology 35 (1985) 907-911
70. Jankovich J., Caskey T.C., Stout J.T., and Butler I.J. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann. Neurol. 23 (1988) 466-469
71. Surtees R., Heales S., and Bowron A. Association of cerebrospinal fluid deficiency of 5-methyltetrahydrofolate, but not S-adenosylmethionine with reduced concentrations of the acid metabolites of 5-hydroxytryptamine and dopamine. Clin. Sci. 86 (1994) 697-702
72. Gopal S.C., Pandey A., Das I., et al. Comparative evaluation of 5-HIAA (5-hydroxy indoleacetic acid) and HVA (homovanillic acid) in infantile hydrocephalus. Childs. Nerv. Syst. 24 (2008) 713-716
73. Pranzatelli M.R., Huang Y.Y., Tate E., et al. Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov. Dis. 13 (1998) 522-528
74. Pranzatelli M.R., Huang Y., Tate E., et al. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome. Ann. Neurol. 37 (1995) 189-197
75. Shaywitz B.A., Cohen D.J., and Bowers M.B. Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology 25 (1975) 72-79
76. Devinsky O., Emoto S., Goldstein D.S., et al. Cerebrospinal fluid and serum levels of dopa, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia 33 (1992) 263-270
77. Duarte S., Sanmarti F., Gonzalez V., et al. Cerebrospinal fluid pterins and neurotransmitters in early severe epileptic encephalopathies. Brain Dev. 30 (2008) 106-111
78. Airaksinen E., Tuomisto L., and Riikonen R. The concentrations of GABA, 5-HIAA and HVA in the cerebrospinal fluid of children with infantile spasms and the effects of ACTH treatment. Brain Dev. 14 (1992) 386-390
79. Silverstein F., and Johnston M.V. Cerebrospinal fluid monoamine metabolites in patients with infantile spasms. Neurology 34 (1984) 102-105
80. Ito M., Okuno T., Mikawa H., and Osumi Y. Elevated homovanillic acid in cerebrospinal fluid of children with infantile spasms. Epilepsia 21 (1980) 387-392
81. Langlais P.J., Wardlow M.L., and Yamamoto H. Changes in CSF neurotransmitters in infantile spasms. Pediatr. Neurol. 7 (1991) 440-445
82. Giroud M., Dumas R., Dauvergne M., et al. 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid of children with febrile convulsions. Epilepsia 31 (1990) 178-181
83. Habel A., Yates C.M., McQueen J.K., Blackwood D., and Elton R.A. Homovanillic acid and 5-hydroxyindoleacetic acid in lumbar cerebrospinal fluid in children with afebrile and febrile convulsions. Neurology 31 (1981) 488-491
84. Kalita J., Kumar S., Vijaykumar K., Palit G., and Misra U.K. A study of CSF catecholamine and its metabolites in acute and convalescent period of encephalitis. J. Neurol. Sci. 252 (2007) 62-66
85. Misra U.K., Kalita J., Pandey S., Khanna V.K., and Nagesh Babu G. Cerebrospinal fluid cathecolamine levels in Japanese encephalitis patients with movement disorders. Neurochem. Res. 30 (2005) 1075-1078
86. Narayan M., Srinath S., Anderson G.M., and Meundi D.B. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol. Psychiatry. 33 (1993) 630-635
87. Cohen D.J., Caparulo B.K., Shaywitz B.A., and Bowers Jr. M.B. Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. CSF homovanillic acid and 5-hydroxyindoleacetic acid. Arch. Gen. Psychiatry. 34 (1977) 545-550
88. Gillberg C., and Svennerholm L. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br. J. Psychiatry. 151 (1987) 89-94
89. Castellanos F.X., Elia J., Kruesi M.J., et al. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry. Res. 52 (1994) 305-316
90. Leckman J.F., Goodman W.K., Anderson G.M., et al. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12 (1995) 73-86
91. Cohen D.J., Shaywitz B.A., Caparulo B., Young J.G., and Bowers Jr. M.B. Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. Arch. Gen. Psychiatry. 35 (1978) 245-250
92. Jacobsen L.K., Frazier J.A., Malhotra A.K., et al. Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Am. J. Psychiatry. 154 (1997) 69-74
93. Blennow M., Zeman J., Dahlin I., and Lagercrantz H. Monoamine neurotransmitters and metabolites in the cerebrospinal fluid following perinatal asphyxia. Biol. Neonate. 67 (1995) 407-413
94. Takaragi S., Horiuchi T., Miyahira H., et al. Cerebrospinal fluid neurotransmitters of the newborn with neonatal asphyxia. Acta. Paediatr. Jpn. 31 (1989) 745-747
95. Nielsen J.B., Bertelsen A., and Lou H.C. Low CSF HVA levels in the Rett syndrome: a reflection of restricted synapse formation?. Brain Dev. 14 (1992) S63-65
96. Lekman A., Witt-Engerström I., Holmberg B., Percy A., Svennerholm L., and Hagberg B. CSF and urine biogenic amine metabolites in Rett syndrome. Clin. Genet. 37 (1990) 173-178
97. Abeling N.G., Duran M., Bakker H.D., et al. Sepiapterin reductase deficiency an autosomal recessive dopa-responsive dystonia. Mol. Genet. Metab. 89 (2006) 116-120
98. Clayton P.T., Surtees R.A., DeVile C., Hyland K., and Heales S.J. Neonatal epileptic encephalopathy. Lancet 361 (2003) 1614
99. Hyland K. The lumbar puncture for diagnosis of pediatric neurotransmitter diseases. Ann. Neurol. 54 (2003) S13-S17
100. Ormazabal A., García-Cazorla A., Fernández Y., Fernández- Álvarez E., Campistol J., and Artuch R. HLPC with electrochemical and fluoresce detection procedures for the diagnosis of inborn errors of biogenic amines and pterines. J. Neurosci. Methods 142 (2005) 153-158
101. Mena M.A., Aguado E.G., and Yebenes J.G. Monoamine metabolites in human cerebrospinal fluid HPLC/EC method. Acta Neurol. Scan. 69 (1984) 218-225
102. Schmidt D., Roznoski M., and Ebert M.H. Qualitative and quantitative high performance liquid chromatographic analysis of monoamine neurotransmitters and metabolites in cerebrospinal fluid and brain tissue using reductive electrochemical detection. Biomed. Chromatogr. 4 (1990) 215-220
103. Yi Y.H., Liao W.P., and Lu X. Simultaneous determination of tryptophan, 5-hydroxytryptophan, 5-hydroxytryptamine, 5-hyroxyindoleacetic acid, 4-hydroxy-3-methoxyphenylacetic acid and 3-methoxy-4-hydroxy-phenylglycol in human cerebrospinal fluid. J. Chromatogr. B. Biomed. Appl. 661 (1994) 144-148
104. Gu Q., Shi X., Yin P., Gao P., Lu X., and Xu G. Analysis of cathecolamines and their metabolites in adrenal gland by liquid chromatography tandem mass spectrometry. Anal. Chim. Acta 609 (2008) 192-200
105. Törnkvist A., Sjöberg P.J., Markides K.E., and Bergquist J. Analysis of cathecolamines and related substances using porous graphitic carbon as separation media in liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 801 (2004) 323-329
106. Sirén H., Mielonen M., and Herlevi M. Capillary electrophoresis in the determination of anionic cathecholamine metabolites from patients' urine. Jour. Chromat. 1032 (2004) 289-297
107. Komori H., Matsuishi T., Yamada S., Ueda N., Yamashita Y., and Kato H. Effect of age on cerebrospinal fluid levels of metabolites of biopterin and biogenic amines. Acta Paediatr. 88 (1999) 1344-1347